## CDNA: CareDx, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.6% in upper entry zone (3.0-6.0%), top 10% cross-sectional ranking. Short-term MRS_5 (3.1%) confirms momentum alignment. Strong momentum (+4.4% 5-day acceleration). Outperforming sector by 7.9%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($18.04)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 4 ($0.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 1 |

**Top Holders:**
- Blackrock Inc.: 9.3% (+2.3%)
- Vanguard Group Inc: 7.3% (-23.6%)
- BAMCO Inc.: 6.1% (+29.5%)
- State Street Corpora: 5.0% (+17.7%)
- Ophir Asset Manageme: 4.3% (+16.1%)

### Key Risks

1. High beta (2.54) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Elevated short interest (13.1%): bears positioning against stock.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +4.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 22.7x attractive for 27% earnings growth. Quality metrics strong (ROE 24%, margin 20%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.39). Institutional flow bullish (9 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.1B |
| Beta | 2.54 |
| 52W Range | $10.96 - $25.95 |
| Short Interest | 13.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.12 |
| Forward P/E | 22.7 |
| Current P/E | 28.8 |
| YoY Growth | 26.9% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from 1.2% to 5.6% (+4.4% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 90th percentile. MRS_5 at 3.1% confirms short-term momentum alignment. Outperforming sector by 7.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.59% (CS: 90) | Strong |
| RSI_14 | 68.6 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 1.124x | Above |
| vs SMA50 | 1.233x | Above |
| vs SMA200 | 1.210x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $19.80
- **Stop Loss:** $18.04 (8.9% risk)
- **Target:** $22.44 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 784
- **Position Value:** $15,523.20
- **Portfolio %:** 15.52%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-03-02 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.14 | $0.28 | +97.6% |
| 2025Q2 | $0.12 | $0.10 | -18.0% |
| 2025Q1 | $0.07 | $0.10 | +46.4% |
| 2024Q4 | $0.15 | $0.18 | +22.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*